A bold finding emerges: administering intravenous iron to patients with iron-deficiency anemia who are also battling an acute bacterial infection can improve survival and raise hemoglobin levels, according to a comprehensive analysis of records from more than 85,000 hospitalized adults.
The study indicates that IV iron is safe in this mixed clinical scenario and, when compared with untreated patients, those who received IV iron showed better overall survival and higher hemoglobin at follow-up. The lead author, Haris Sohail, MD, a hematology-oncology fellow at Charleston Area Medical Center in West Virginia, emphasizes that IV iron is already a standard treatment for severe iron-deficiency anemia. Its use in patients with concurrent acute bacterial infections has been contentious, given laboratory concerns that iron can promote bacterial growth in some settings. Although human data confirming this effect are lacking, guidelines have historically advised caution or avoidance of IV iron during active infections.
To explore this issue, the researchers mined a large, de-identified U.S. database covering adult inpatients (age 18 and older) with iron-deficiency anemia who were hospitalized for an acute bacterial infection between 2000 and 2024. The cohort included more than 85,000 individuals with the five most common acute infections treated in hospitals: pneumonia (over 27,000), urinary tract infections (over 23,000), MRSA bacteremia or bloodstream infection (over 15,000), cellulitis (over 13,000), and colitis of the colon (over 7,000), plus 143 meningitis cases.
The team compared outcomes between those who received IV iron and those who did not, focusing on mortality within 14 and 90 days, duration of hospital stay, and the change in hemoglobin levels from baseline to 60–90 days after treatment.
Across all infections except meningitis, IV iron was associated with a statistically significant reduction in short- and longer-term death and with larger increases in hemoglobin compared with no IV iron. In meningitis patients, IV iron did not improve survival, though it did not worsen outcomes either.
Dr. Sohail noted that the most pronounced survival gains appeared in pneumonia, MRSA bacteremia, and colitis patients. The slightly longer hospital stays observed with IV iron—roughly four to six hours on average—were not judged to be clinically meaningful.
The relatively small number of meningitis cases likely contributed to the non-significant survival signal in that subgroup. The study’s design reflects associations rather than proven causation, since it relied on retrospective records and could not control iron dose details or pinpoint specific pathogens. The findings are most relevant to hospitalized adults with both iron-deficiency anemia and an active bacterial infection, and they underscore the need for randomized trials to confirm causality.
Ultimately, the authors suggest that IV iron could be considered as a safe supplementary therapy in this patient population, while acknowledging the necessity of randomized controlled trials to validate these observations and guide practice.
Haris Sohail, MD, will present these results in a plenary session at the Orange County Convention Center on Sunday, December 7, 2025, at 3:25 p.m. Eastern Time.
What do you think: should IV iron be routinely considered in such cases, or should caution prevail until randomized data solidify its role? Share thoughts below.
